CJC-1295 (No DAC) vs Selank: Mechanism, Half-Life & Research Use

Direct Comparison: CJC-1295 (No DAC) vs Selank at a Glance

CJC-1295 (No DAC) and Selank serve distinct biological targets in research models. CJC-1295 (No DAC) is a growth hormone-releasing hormone (GHRH) analog that stimulates pulsatile pituitary GH release for somatotropic research. Conversely, Selank is a synthetic tuftsin-derived neuropeptide modulating GABAergic transmission and BDNF expression for neurochemical and immunomodulatory study designs.

To assist laboratory personnel in selecting the appropriate reference compound for cellular or animal models, the following matrix summarizes the fundamental chemical and operational differences between these two synthetic peptides:

| Research Criteria | CJC-1295 (No DAC) | Selank | | :--- | :--- | :--- | | **Primary Receptor Target** | Growth Hormone-Releasing Hormone Receptor (GHRHR) | Allosteric modulator of GABA-A receptors; BDNF pathways | | **Mechanistic Class** | Synthetic GHRH Secretagogue / Somatotropimetic | Synthetic Tuftsin Analog / Regulatory Neuropeptide | | **Reported In Vivo Half-Life** | ~30 minutes (pulsatile kinetic profile) | ~2 to 10 minutes (rapid enzymatic degradation) | | **Solubility Profile** | Water-soluble; rehydrates efficiently in Bacteriostatic Water | Water-soluble in aqueous buffers (PBS or sterile water) | | **Typical Preclinical Models** | Rodent models of GH expression, cellular proliferation, tissue repair | Rodent models of anxiety, cognitive processing, immune modulation | | **Standard Laboratory Format** | Lyophilized powder (2mg / 5mg vial formats) | Lyophilized powder (5mg / 10mg vial formats) |

When designing protocols, investigators should consult the full catalog of research peptides to review raw material specifications and batch-specific documentation.

Mechanistic Framework of CJC-1295 (No DAC)

CJC-1295 (No DAC), also referred to as Modified GRF (1-29), is a 29-amino-acid synthetic peptide representing a truncated and bio-engineered derivative of endogenous growth hormone-releasing hormone (GHRH). Endogenous GHRH undergoes rapid cleavage in vivo via dipeptidyl peptidase-IV (DPP-IV). To counteract this metabolic instability, CJC-1295 (No DAC) incorporates specific amino acid substitutions—namely D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—which significantly enhance enzymatic resistance while maintaining affinity for the GHRH receptor located on anterior pituitary somatotrophs.

Upon binding to the GHRH receptor, CJC-1295 (No DAC) activates the Gs alpha protein-coupled receptor subunit, triggering intracellular adenylate cyclase activity. This cascade increases cyclic adenosine monophosphate (cAMP) levels and activates protein kinase A (PKA), culminating in the transcription and exocytosis of growth hormone (GH) storage vesicles. Because CJC-1295 (No DAC) lacks the Drug Affinity Complex (DAC) maleimide moiety, it does not covalently bind to endogenous serum albumin. Consequently, it exhibits a short half-life (~30 minutes) that preserves natural physiological GH pulsatility without causing continuous, non-physiological elevation.

In cell culture and animal tissue models, this controlled amplification of GH output subsequently upregulates hepatic production of Insulin-like Growth Factor 1 (IGF-1). Researchers frequently utilize high-purity CJC-1295 (No DAC) for research to analyze somatotropic signal transduction, cellular proliferation, collagen synthesis, and systemic metabolic rate modulation in tissue repair assays.

Mechanistic Framework of Selank

Selank is a synthetic regulatory neuropeptide developed via the modification of the natural immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg). By appending a Pro-Gly-Pro tripeptide sequence to the C-terminus, developers created a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) that demonstrates enhanced structural stability and bioactivity across central nervous system (CNS) and immune system models.

Unlike classic G-protein coupled receptor ligands, Selank exerts complex, multi-target modulatory effects. Preclinical observations indicate that Selank acts as an allosteric modulator of the GABA-A receptor complex, altering affinity for endogenous gamma-aminobutyric acid without displaying the addictive or sedating binding kinetics associated with classical benzodiazepines. Simultaneously, Selank influences monoamine neurotransmitter metabolisms, regulating serotonin (5-HT) and dopamine turnover in cortical and hippocampal brain regions.

At the gene expression level, in vitro studies demonstrate that Selank rapidly upregulates mRNA expression of Brain-Derived Neurotrophic Factor (BDNF) and its primary tyrosine kinase receptor, TrkB, within neuronal cultures. Additionally, due to its structural lineage from tuftsin, Selank modulates cytokine expression—specifically interleukin-6 (IL-6) and balance between Th1/Th2 immune responses—making it a prominent subject in neuroimmunology and neuroprotective research.

Receptor Binding Affinity & Target Kinetics

The molecular targets of CJC-1295 (No DAC) and Selank do not overlap, establishing distinct cellular pathways for experimental inquiry. CJC-1295 (No DAC) demonstrates high selective affinity for the membrane-bound GHRH receptor ($EC_{50}$ values in the nanomolar range), initiating downstream nuclear translocation of CREB (cAMP response element-binding protein). This pathway is localized primarily to pituitary tissue and peripheral tissues expressing extra-pituitary GHRH receptors.

Selank, conversely, exhibits no affinity for GHRH receptors or somatotropic pathways. Its receptor interaction profile centers on neural membrane complexes and immune cells. In binding assays, Selank displays subtle, non-competitive binding to GABAergic complexes, altering chloride ion channel open times, while modulating enkephalinase enzymes to suppress the degradation of endogenous opioids (such as leu-enkephalin).

Understanding these target differences allows researchers to isolate specific physiological systems: CJC-1295 (No DAC) provides a targeted tool for somatotropic endocrine research, whereas Selank serves as a multi-modal agent for central nervous system and neuro-immune signaling assays.

Comparative Pharmacokinetics and Half-Life Profiles

Pharmacokinetic considerations dictate the administration schedules and sampling intervals within laboratory protocols. The half-life of CJC-1295 (No DAC) in rodent plasma is approximately 30 minutes. While far shorter than DAC-bound variants (which can extend past 6 days), this profile provides sufficient stability to produce robust, physiological GH pulses lasting 2 to 3 hours post-exposure, after which baseline levels are restored.

Selank exhibits a remarkably rapid systemic elimination profile, with a native plasma half-life measured in minutes due to ubiquitous endopeptidases and carboxypeptidases in biological fluids. However, its physiological effects—particularly downstream transcriptional changes in BDNF expression and neurochemical shifts—persist significantly longer than the circulating peptide itself. In preclinical models, transient exposure to Selank triggers neurochemical alterations that endure for several hours.

Because both compounds possess rapid kinetic profiles relative to long-acting depot peptides, accurate reconstitution procedures are necessary to preserve peptide integrity prior to assays. Researchers should utilize our interactive reconstitution calculator to determine precise molar concentrations and solvent volumes for laboratory preparations.

Preclinical Research Protocols and In Vitro Assays

In preclinical laboratory settings, experimental designs utilizing CJC-1295 (No DAC) typically target endocrine dynamics, protein translation rates, or musculoskeletal regeneration. Primary pituitary cell cultures exposed to CJC-1295 (No DAC) are routinely assessed via ELISA or radioimmunoassays to quantify temporal GH secretion curves. In rodent models, researchers evaluate tissue regeneration by quantifying serum IGF-1 markers, collagen mRNA expression, and nitrogen retention metrics.

Experimental protocols involving Selank focus predominantly on behavioral, cognitive, and immunological parameters. Rodent models subjected to chronic mild stress or elevated plus maze assays are evaluated for behavioral responses, while hippocampal tissue homogenates are analyzed via RT-qPCR to measure BDNF transcription levels. Furthermore, cell culture models incorporating peripheral blood mononuclear cells (PBMCs) utilize Selank to measure changes in gene expression for inflammatory cytokines.

Researchers seeking detailed documentation regarding purity verification, sequence confirmation, and physical properties for either compound can access our public repository of Certificate of Analysis (COA) documentation prior to design execution.

Comparative Class Evaluation: Related Somatotropes and Regulatory Peptides

To contextualize CJC-1295 (No DAC) within its functional class, investigators frequently contrast it with other secretagogues. For example, Sermorelin represents the un-modified sequence of native GHRH (1-29), exhibiting a shorter half-life (~10–12 minutes) than CJC-1295 (No DAC) due to lack of amino acid modifications at DPP-IV cleavage sites. When paired with ghrelin mimetics such as Ipamorelin, CJC-1295 (No DAC) exhibits synergistic growth hormone release via dual-receptor activation.

Similarly, in neuropeptide research, Selank is frequently evaluated alongside its structural counterpart Semax. While both compounds derive from endogenous regulatory peptides and share neuroprotective characteristics, Semax stems from an ACTH (4-10) fragment and preferentially influences melanocortin pathways and neurotrophic factors, whereas Selank focuses on GABAergic pathways and tuftsin-mediated immunomodulation.

Laboratory directors analyzing multiple pathways can explore our broader research library hub to evaluate comparative literature across somatotropic, metabolic, and neurobiological peptide classes.

Quality Controls: HPLC, MS Verification, and Endotoxin Standards at PX1

Precision in peptide research requires uncompromising compound purity and batch consistency. PX1 Research synthesizes all peptide reagents within state-of-the-art, GMP-compliant facilities located in the USA. Every lot undergoes rigorous testing in an ISO 17025 accredited analytical laboratory prior to release.

Purity is verified via High-Performance Liquid Chromatography (HPLC), guaranteeing a minimum of 98% chemical purity. Mass Spectrometry (MS) analysis is performed simultaneously to confirm exact molecular weight and amino acid sequence accuracy, ensuring the absence of deletion sequences or residual counter-ions.

Furthermore, because bacterial endotoxins can severely artifact cell culture assays and immune-response research, PX1 subjects all lyophilized lots to stringent Limulus Amebocyte Lysate (LAL) testing, guaranteeing endotoxin levels below 0.01 EU/mg. All products ship rapidly with same-day fulfillment (Monday through Friday) from our dual logistics centers in California and Arizona.

For institutional procurement, high-volume academic laboratories, or contract research organizations requiring bulk custom packaging, details regarding commercial accounts are available through our wholesale lab portal.

Matching Research Objectives to Experimental Compounds

Selecting between CJC-1295 (No DAC) and Selank depends entirely on the primary biological axis under investigation. Laboratories focusing on endocrine dynamics, somatopause models, cellular protein synthesis, or musculoskeletal tissue repair will find CJC-1295 (No DAC) to be the appropriate experimental agent due to its target specificity for the GHRH receptor.

Conversely, research protocols focused on neurobiology, central neurotransmitter modulation, cognitive mechanisms, or neuro-immune crosstalk require the unique neuroactive profile of Selank. Because these reagents act through mutually exclusive signaling pathways, they cannot serve as functional substitutes for one another in controlled trial designs.

All products supplied by PX1 Research are strictly intended for laboratory research use only in vitro or in animal models, and are explicitly not for human or veterinary clinical use.